A study is underway in Atlanta to test an Alzheimer's drug that's already showing real promise.
Intepirdine could become the first new FDA-approved drug for Alzheimer's in more than a decade.
"It causes a certain area of the brain to release the transmitter acetylcholine, and acetylcholine is the main memory transmitter," said Atlanta neurologist Dr. Dennis Lacey with NeuroTrials Research, Inc.
Dr. Lacey is working with Atlanta patients as part of a worldwide clinical trial called MINDSET.
It's designed to study whether Interpirdine can slow the progression of Alzheimer's when taken together with Donepezil, the generic form of Aricept, the most widely used medicine to treat Alzheimer's today.
"Studies they've done so far have shown very positive results when these two medicines are used together, in terms of improving cognitive function and improving activities of daily living," Dr. Lacey said.
The final phase of testing is underway, Dr. Lacey is looking to enroll more patients between the ages of 50 and 85 with mild to moderate Alzheimer's or dementia.
NeuroTrials Research in Atlanta (404-851-9934) is one of almost 200 study sites around the world.